These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors. Shi X; Lin X; Hu R; Sun N; Hao J; Gao C Am J Alzheimers Dis Other Demen; 2016 Aug; 31(5):405-12. PubMed ID: 26769920 [TBL] [Abstract][Full Text] [Related]
45. Effective pharmacological management of Alzheimer's disease. Atri A Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392 [TBL] [Abstract][Full Text] [Related]
46. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study. Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135 [TBL] [Abstract][Full Text] [Related]
47. [Current therapy of patients with dementia]. Fuchsberger T; Möller HJ; Hampel H MMW Fortschr Med; 2003 May; 145 Suppl 2():49-52, 54. PubMed ID: 14579485 [TBL] [Abstract][Full Text] [Related]
48. Longitudinal medication usage in Alzheimer disease patients. Zhu CW; Livote EE; Kahle-Wrobleski K; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y Alzheimer Dis Assoc Disord; 2010; 24(4):354-9. PubMed ID: 20625271 [TBL] [Abstract][Full Text] [Related]
50. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Jones RW Int J Geriatr Psychiatry; 2010 Jun; 25(6):547-53. PubMed ID: 20049770 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102 [TBL] [Abstract][Full Text] [Related]
52. [Effect of drugs against dementia]. Engedal K; Braekhus A; Gjerstad L Tidsskr Nor Laegeforen; 2004 Jun; 124(12):1641-2. PubMed ID: 15229711 [No Abstract] [Full Text] [Related]
53. How do we treat people with dementia in Croatia. Mimica N; Presecki P Psychiatr Danub; 2010 Jun; 22(2):363-6. PubMed ID: 20562784 [TBL] [Abstract][Full Text] [Related]
54. [Treatment of dementia]. Blom K; van den Elsen GAH; Koek HL; Sanders JB; Kruithof HC; Claassen JAHR Ned Tijdschr Geneeskd; 2017; 161():D1851. PubMed ID: 28936936 [TBL] [Abstract][Full Text] [Related]
56. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808 [TBL] [Abstract][Full Text] [Related]
57. [Updated Dementia guideline: reflections from primary care]. Perry M; Moll van Charante EP Ned Tijdschr Geneeskd; 2015; 159():A8939. PubMed ID: 25873226 [TBL] [Abstract][Full Text] [Related]
58. The emperor has no clothes: dementia treatment on the eve of the aging era. Royall DR J Am Geriatr Soc; 2005 Jan; 53(1):163-4. PubMed ID: 15667396 [No Abstract] [Full Text] [Related]
59. [Treatment of degenerative dementia disorders--who should be treated?]. Hasselbalch SG; Kampmann JP Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606 [TBL] [Abstract][Full Text] [Related]
60. Drugs to treat Alzheimer's disease. J Psychosoc Nurs Ment Health Serv; 2009 Apr; 47(4):13-4. PubMed ID: 19437925 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]